Use of Lidocaine for Analgesia in Children and Adolescents
Use of Lidocaine for Analgesia in Children and Adolescents
Use of lidocaine in patients with other local anesthestics may increase the risk for systemic toxicity. Administration of lidocaine in patients receiving Class I antiarrhythmic agents may produce additive or synergistic effects on cardiac conduction and is not recommended. Administration of lidocaine and dihydroergotamine may lead to extreme elevations of blood pressure. Lidocaine concentrations may be elevated when given with drugs metabolized by CYP1A2 or CYP3A4, such as amprenavir, atazanavir, dalfopristin, darunavir, delavirdine, etravirine, fosamprenavir, indinavir, lopinavir, nevirapine, quinupristin, ritonavir, saquinavir, and telaprevir. It is also recommended that drugs which impair hepatic blood flow, such as cimetidine and beta-adrenergic blocking agents, not be used in patients receiving continuous lidocaine infusions because of the potential for reduced clearance.
Drug Interactions
Use of lidocaine in patients with other local anesthestics may increase the risk for systemic toxicity. Administration of lidocaine in patients receiving Class I antiarrhythmic agents may produce additive or synergistic effects on cardiac conduction and is not recommended. Administration of lidocaine and dihydroergotamine may lead to extreme elevations of blood pressure. Lidocaine concentrations may be elevated when given with drugs metabolized by CYP1A2 or CYP3A4, such as amprenavir, atazanavir, dalfopristin, darunavir, delavirdine, etravirine, fosamprenavir, indinavir, lopinavir, nevirapine, quinupristin, ritonavir, saquinavir, and telaprevir. It is also recommended that drugs which impair hepatic blood flow, such as cimetidine and beta-adrenergic blocking agents, not be used in patients receiving continuous lidocaine infusions because of the potential for reduced clearance.
